Last updated March 30
Updates and Resources for Pitt Researchers
The Office of the Senior Vice Chancellor for Research (SVCR) has compiled guidance specific to the Pitt research community. Please visit the SVCR website for continually updated information and resources.
Guidelines for Essential Research Personnel
While scientific research and development continue at the University of Pittsburgh, all in-person work must be deemed essential and conducted in a manner fully consistent with guidance to minimize transmission risk of COVID-19. Consistent with Governor Tom Wolf’s orders, the the University has established guidelines that apply to all Pitt research activities.
Coordination of COVID-19 Research
Research teams at the University of Pittsburgh and UPMC have mobilized to plan and implement clinical trials and clinical research studies related to COVID-19. Given the rapidity of the spread of disease, timely and efficient implementation of studies are critical to their success.
To support and facilitate these studies, the Clinical and Translational Science Institute (CTSI) is mobilizing to help coordinate resources, expertise, research tools and lab capabilities. CTSI will catalogue every Pitt or UPMC COVID-19-related research protocol involving human subjects and/or associated biosamples, electronic health records and other data. This will enable Pitt and UPMC to:
- Identify collaborative opportunities among study teams
- Coordinate with HRPO to streamline regulatory submissions
- Assess researchers’ needs
- Provide research tools (e.g., electronic consents)
- Leverage expertise (e.g., study design)
- Link to institutional resources (e.g., biobanking, Health Record Research Request (R3))
- Harmonize data elements across studies
- Help provide integration with national and international research efforts
All principal investigators planning or conducting COVID-19-related studies should submit a brief description of their proposal. Funding opportunities are available from multiple sources. Please send requests for additional information to firstname.lastname@example.org.
Studying the 2019 Novel Coronavirus
Current CDC and Pitt requirements indicate that work with or culturing of the the virus that causes COVID-19 (SARS-CoV-2) must be performed at Biosafety Level 3. A CDC Import Permit for SARS-CoV-2 is required to obtain virus isolates and/or patient samples from cases under investigation. The import permit process is now electronic through the CDC. At present, SARS-CoV-2 is not a select agent; however, it should be noted that Pitt is NOT currently registered for work with SARS-CoV-1, which is a select agent. Any investigator wishing to initiate research using SARS-CoV-1, MERS-CoV or SARS-CoV-2 must inform the RO/ARO in Environmental Health and Safety at 412-624-9505.